How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

The changing face of drug development and the end of the blockbuster era demands a monumental shift in drug development strategies. Making use of a wider range of resources to inform research and not just focusing on clinical trial data can provide greater insights into treatments and patients. Real-world data taken from patients outside of the clinical research setting is one such resource that is gradually becoming more called upon. Aiden Flynn, CEO of clinical trial data and design experts, Exploristics, explores the current data environment and its data pools and how these can be fully utilised for the benefit of advancing research.

How real-world data can revolutionise drug development

Types of data

Real-world data is a resource that can complement traditional clinical trial research to provide a more comprehensive picture and generalise findings to larger populations of patients. Real-world data comes from a variety of sources: from electronic health records (EHR) to medical insurance claims. There is also a new breed of data that is emerging via wearable technologies and genetic profiling kits such as 23 and me, both of which have the potential to reveal deeper insights into the base line health status of normal healthy subjects not presenting as patients or taking part in clinical trials.

Data pools

The growing number of data sources via various organisations offer a vital opportunity to glean useful information for healthcare decision-makers. Many developed countries now have high-value, real-world data pools through healthcare systems, charities and disease registries. There is a considerable need to exploit these wide-ranging public healthcare data sources effectively in order to ensure that this information can be fed into the system and provide useful input for researchers and other stakeholders along the drug development pipeline. To realise the full potential of real-world data gleaned from public and private sector bodies requires a Learning Healthcare System. Based on EHRs and other routinely collected healthcare data, a Learning Healthcare System allows data to be continuously fed into the system to improve understanding of treatment pathways and outcomes. As these systems evolve the potential exists to plug the output into platforms that help develop novel medical interventions and streamline patient care pathways.

Compiling and using real-world data in this way would bolster research from clinical trials and facilitate the integration of all medical research. For it to become a reality, healthcare bodies must be equipped with the right technologies to facilitate good data capture and ensure that any captured data is subjected to the right analytical methods. There also needs to be improved standards around consent, ethics and data access. Fully digitising and standardising data in the healthcare field will require a joint effort on an international scale and ensure that Learning Healthcare Systems can be fully implemented and utilised.

A transformation

The pools of rich real-world data that have been collected over the years across different countries offer a new and evolving prospect for bringing real-world insight into drug development. The liberation of this real-world data via state-of-the-art, digitised learning systems could transform the development of new medicines and the delivery of healthcare. The data revolution is only just beginning but it is set to be a significant transformation.

Read More

Related news

iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Pharma packaging companies commit to supply for COVID-19 fight

Pharma packaging companies commit to supply for COVID-19 fight

16 Jun 2020

Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
India says shipments of hydroxychloroquine will resume after US exerts pressure

India says shipments of hydroxychloroquine will resume after US exerts pressure

7 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more